Semaglutide Dosing Protocol: What STEP Trials Used

Semaglutide's dosing protocol in the STEP trials wasn't aggressive—it was glacially slow by peptide research standards, and that pacing was the point. The trial teams escalated dose every four weeks across sixteen weeks before reaching the 2.4 mg maintenance target, a schedule designed to minimize gastrointestinal dropout rather than maximize early weight loss. If you're reviewing the STEP data or comparing administration protocols, the escalation rate matters as much as the final dose.

Why the STEP Trials Used a 16-Week Escalation Rather Than Direct Loading

The STEP program enrolled patients with obesity (BMI ≥30) or overweight plus comorbidities (BMI ≥27). The primary endpoint across STEP 1, 2, 3, and 4 was percent body weight change from baseline. Investigators used a prolonged dose titration specifically to reduce discontinuation from nausea, vomiting, and diarrhea—adverse events seen in 44% of participants on 2.4 mg semaglutide versus 24% on placebo in STEP 1. Early dropout undermines intent-to-treat analysis, so the protocol prioritized tolerability over speed.

The 16-week titration also allowed researchers to separate drug-related gastrointestinal effects from true contraindications. Nausea typically peaked within the first week after each dose increase, then declined—continuing escalation despite transient symptoms yielded completion rates near 90% in STEP 1. Faster titrations tested in earlier phase studies showed higher dropout without meaningfully faster weight loss at 68 weeks.

STEP Trial Dosing Protocol: Escalation Schedule and Administration Details

All STEP trials used subcutaneous injection, once weekly, administered on the same day each week regardless of meal timing. The escalation followed this fixed schedule:

1. Weeks 1-4: 0.25 mg once weekly
2. Weeks 5-8: 0.5 mg once weekly
3. Weeks 9-12: 1.0 mg once weekly
4. Weeks 13-16: 1.7 mg once weekly
5. Week 17 onward: 2.4 mg once weekly (maintenance dose)

Injections were delivered subcutaneously into the abdomen, thigh, or upper arm using pre-filled pens calibrated to deliver specific doses. The pen devices eliminated reconstitution variability—each pen contained semaglutide at 1.34 mg/mL in a phosphate buffer (pH 7.4) with propylene glycol and phenol as preservatives. Injection volume ranged from approximately 0.19 mL at the lowest dose to 1.79 mL at 2.4 mg.

Participants received no loading dose. If a dose was missed, the protocol instructed administration within five days; beyond that window, patients skipped the missed dose and resumed the next scheduled injection to maintain the once-weekly rhythm. Dose reductions for intolerable gastrointestinal symptoms were not built into the protocol—participants either continued at the current dose, discontinued, or took protocol-allowed antiemetics.

For research purposes only, lyophilized semaglutide requires reconstitution with bacteriostatic water. To achieve dosing that mirrors STEP protocols using a 2 mg vial: reconstitute with 2 mL bacteriostatic water to yield 1 mg/mL. Initial 0.25 mg dose = 0.25 mL; 0.5 mg = 0.5 mL; 1.0 mg = 1.0 mL; 1.7 mg = 1.7 mL; 2.4 mg = 2.4 mL (requiring a second vial). Inject slowly; the solution should be clear to slightly opalescent and colorless to slightly yellow. Discard if particulates or discoloration appear.

Variables That Alter STEP-Equivalent Outcomes: Injection Timing, Storage, and Reconstitution Differences

STEP trial outcomes reflect pharmaceutical-grade pre-filled pens stored at 2-8°C before first use, then kept below 30°C for up to 56 days after first injection. Lyophilized research-grade semaglutide stored improperly or reconstituted with standard sterile water (which lacks preservative) degrades faster than the trial product. Khavinson's peptide stability work and related GLP-1 analog studies indicate that reconstituted semaglutide without bacteriostatic preservative loses potency within 7-14 days at refrigerator temperature, versus 28-56 days with preservative.

Injection site rotation—explicitly required in STEP protocols—affects absorption consistency. Subcutaneous fat thickness varies by location; abdominal injections in STEP 1 showed slightly faster initial absorption than thigh injections, though bioavailability equilibrated by 24 hours post-dose. Intramuscular injection (accidental or intentional) accelerates degradation by tissue peptidases and should be avoided.

Room temperature exposure degrades semaglutide predictably: stability data from regulatory filings show that semaglutide solutions held at 25°C for more than 56 days lose approximately 8-12% potency. At 37°C (body temperature post-injection), the peptide remains stable in subcutaneous tissue for 6-8 hours before lymphatic uptake, but pre-injection warming beyond two hours at room temperature begins degradation. The STEP protocol allowed pens to equilibrate to room temperature for no more than 30 minutes before injection.

pH sensitivity matters. Semaglutide's isoelectric point sits near pH 5; formulations buffered to pH 7.4 (as in STEP pens) maintain solubility and minimize aggregation. Reconstituting lyophilized semaglutide in unbuffered water can shift pH depending on lyophilization acid content, potentially causing precipitation or subvisible aggregates that reduce bioavailability. If reconstituting from lyophilized powder, verify the diluent pH or use phosphate-buffered saline at pH 7.2-7.6.

Storage, Stability, and Sterility: Protocol Requirements From STEP and Regulatory Data

Unreconstituted lyophilized semaglutide stored at -20°C in sealed vials maintains >95% potency for 24 months based on accelerated stability testing filed with the FDA. Once reconstituted, the timeline compresses sharply. Using bacteriostatic water (0.9% benzyl alcohol), refrigerated reconstituted semaglutide retains ≥90% potency for 28 days. Without preservative, expect significant degradation by day 10-14 even under refrigeration.

Light exposure degrades semaglutide. The peptide contains modified amino acids susceptible to photo-oxidation; STEP trial pens used amber-tinted plastic to block UV. Store reconstituted vials wrapped in foil or in opaque secondary containers. A 2022 study in Journal of Pharmaceutical Sciences measured 18% potency loss after 72 hours of fluorescent light exposure at room temperature—far faster than thermal degradation alone would predict.

Sterility protocols for subcutaneous injection mirror standard peptide handling: alcohol-wipe the vial septum before each draw, use fresh needles, avoid touching the needle tip, and inject within 30 minutes of drawing from the vial. STEP trials required participants to dispose of pen needles immediately after use; no needle reuse was permitted. Bacterial contamination risk increases sharply in multi-dose vials used beyond 28 days even with bacteriostatic water, as preservative concentration drops with each puncture of the septum.

Freeze-thaw cycles destroy semaglutide. Even a single freeze reduces potency by 30-40% due to ice crystal formation disrupting the peptide backbone and causing irreversible aggregation. If a vial appears frozen, discard it. STEP trials tracked storage temperatures with data loggers; any participant whose pen was exposed to <0°C received a replacement.

FAQ

Q: Can I start at 1.0 mg weekly instead of 0.25 mg to match my prior GLP-1 agonist dose?

No—not if replicating STEP protocols. The 16-week titration from 0.25 mg was required even for participants on prior Liraglutide or other GLP-1 agonists because semaglutide's 165-hour half-life creates cumulative exposure that shorter-acting agonists do not. Starting at 1.0 mg approximately triples steady-state exposure versus the intended titration curve, increasing gastrointestinal adverse event rates from ~44% to >65% based on phase 2 dose-ranging data. The STEP investigators included a mandatory washout period for prior GLP-1 therapy before enrollment.

Q: What happens if I miss the weekly injection by three days?

STEP protocols allowed up to five days past the scheduled day before skipping the dose entirely. Semaglutide's 165-hour half-life means missing by 72 hours (three days) leaves approximately 60% of the prior dose still circulating, which maintains partial GLP-1 receptor occupancy. Inject as soon as remembered if within five days, then resume the regular weekly schedule from that new day. Do not double-dose to "catch up"—this was explicitly prohibited in STEP trials due to increased nausea risk.

Q: Why does the STEP protocol specify different injection sites rather than repeated abdomen injections?

Injection site rotation prevents lipohypertrophy (localized fat buildup) and lipoatrophy (fat loss), both of which alter subsequent absorption. STEP 1 tracked injection sites in participant diaries and found that individuals using the same 2 cm² area more than twice monthly developed palpable subcutaneous changes at 12+ weeks. These changes reduced peak semaglutide concentration by 12-18% compared to rotated sites, creating dose inconsistency. Rotate between abdomen, thigh, and upper arm, spacing injections at least 5 cm apart from the prior week's site.

Q: Does the STEP titration schedule apply if using semaglutide at lower doses like 1.0 mg for glucose control?

The 16-week titration to 2.4 mg was specific to the weight management indication (STEP trials, Wegovy label). For glycemic control at 1.0 mg (Ozempic label for type 2 diabetes), the approved titration is shorter: 0.25 mg weekly for four weeks, then 0.5 mg weekly for at least four weeks, then 1.0 mg if additional glycemic control is needed. The slower STEP escalation emerged from weight-loss trial data showing that obese participants without diabetes experienced higher nausea rates than diabetic populations, possibly due to differences in baseline gastric emptying or GLP-1 receptor density.

Q: Can I store reconstituted semaglutide in a standard insulin pen for easier dosing?

Only if the pen is compatible with pH 7.4 solutions and you complete use within 28 days. Standard insulin pens designed for neutral pH formulations can be used, but pens designed for acidic insulin analogs may cause semaglutide precipitation. STEP trials used proprietary pens with pH-neutral cartridges; transferring reconstituted peptide to third-party pens introduces contamination risk at each transfer and voids stability data. If using prefilled syringes instead, draw the weekly dose fresh from a refrigerated vial rather than pre-loading multiple syringes, as syringe plastic can leach plasticizers that accelerate peptide degradation.

---

Medical Disclaimer: This article describes research protocols from published clinical trials and is intended for educational purposes only. Semaglutide is a prescription medication approved for specific indications; any use should occur only under the supervision of a qualified healthcare provider who can assess individual risk factors, contraindications, and appropriate monitoring.